Abbott Park, Illinois, U.S., October 5, 2026
Abbott has received U.S. Food and Drug Administration (FDA) approval for new capabilities of its CardioMEMS HF System, expanding how patients with heart failure can access and engage with information about their condition. The updated system will allow U.S. CardioMEMS patients, when enabled by their care teams, to view their pulmonary artery pressure (PAP) readings and trends through the CardioGuide HF App on their smartphones. The new capabilities are designed to strengthen communication between patients and healthcare professionals and support more active participation in heart failure management between routine medical appointments. Abbott plans to make the CardioGuide HF App and Dynamic Treatment Plan capabilities available later in 2026.
CardioMEMS Brings Pressure Monitoring to Patients
The new FDA-approved capabilities give patients greater visibility into pulmonary artery pressure, an important physiological measurement used to monitor heart failure. Rising PAP can be an early indicator that heart failure is worsening and may occur weeks before noticeable symptoms such as shortness of breath, swelling, or weight gain develop. The CardioMEMS HF System uses a small implanted sensor positioned in the pulmonary artery to measure pressure remotely. Previously, these readings have primarily been used by healthcare professionals through Abbott’s remote monitoring infrastructure to identify changes and guide treatment. With the new CardioGuide HF App functionality, patients can also see their own pressure readings and trends on compatible smartphones, providing a more direct connection to information about their heart condition.
Dynamic Treatment Plans Support Personalized Care
The updated CardioMEMS HF System also introduces Dynamic Treatment Plan (DTP) capabilities, allowing clinicians to establish personalized medication adjustment plans based on changes in a patient’s pulmonary artery pressure. When enabled by the care team, medication adjustment instructions can be delivered directly to patients through the CardioGuide HF App. This approach is designed to provide patients with timely treatment guidance while maintaining communication with their healthcare teams between office visits. Abbott says the combination of remote hemodynamic monitoring and patient-facing digital tools represents an evolution in heart failure management, allowing care teams to respond to changes in a patient’s condition while helping individuals better understand why treatment adjustments may be recommended. The system is intended to support an ongoing care relationship rather than relying solely on periodic clinical appointments.
Advertisement
Abbott Expands Digital Heart Failure Management
The CardioMEMS HF System is a wireless remote hemodynamic monitoring platform designed for heart failure management. Its implanted pressure sensor communicates measurements through the system’s patient-care network, enabling clinicians to monitor pulmonary artery pressure and proactively adjust treatment. Abbott says the platform is supported by more than a decade of clinical evidence and has been shown in studies to reduce heart failure hospitalizations and mortality risk. The newly approved patient-facing capabilities build on that monitoring infrastructure by extending access to pressure trends and personalized care instructions. For patients living with chronic heart failure, the ability to view pressure trends may provide greater awareness of changes that are not yet accompanied by symptoms, while the Dynamic Treatment Plan can facilitate individualized communication from the care team. Abbott’s latest regulatory milestone highlights the growing role of digital health and remote patient monitoring in cardiovascular care, combining an implanted medical device with smartphone-based patient engagement. The CardioGuide HF App and Dynamic Treatment Plan are expected to become available later this year, expanding the functionality of the CardioMEMS platform for eligible U.S. patients.
Source: Abbott press release
